Argenx
ARGX
#435
Rank
NZ$99.68 B
Marketcap
NZ$1,585
Share price
-0.55%
Change (1 day)
10.89%
Change (1 year)
Argenx is a Dutch company that develops antibody therapies to fight autoimmune diseases and cancer.

EPS for Argenx (ARGX)

EPS in 2026 (TTM): NZ$27.23

According to Argenx 's latest financial reports the company's current EPS (TTM) is NZ$28.07. In 2025 the company made an earnings per share (EPS) of NZ$37.43 an increase over its 2024 EPS that were of NZ$24.71.

EPS history for Argenx from 2011 to 2026

Annual EPS

Year EPS Change
2026 (TTM)NZ$27.23-27.25%
2025NZ$37.4351.44%
2024NZ$24.71-369.77%
2023NZ-$9.16-60.46%
2022NZ-$23.1763.33%
2021NZ-$14.19-40.37%
2020NZ-$23.79183.47%
2019NZ-$8.39123.09%
2018NZ-$3.7654.93%
2017NZ-$2.4314.07%
2016NZ-$2.1313.05%
2015NZ-$1.88-36.34%
2014NZ-$2.96209.04%
2013NZ-$0.96-33.99%
2012NZ-$1.45185.59%
2011NZ-$0.51